Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF – Get Free Report) was the recipient of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 7,595 shares, a drop of 72.6% from the July 15th total of 27,721 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.
Laboratorios Farmaceuticos Rovi Stock Performance
OTCMKTS:LABFF opened at C$67.17 on Thursday. The business’s fifty day moving average is C$65.79 and its 200 day moving average is C$65.84. Laboratorios Farmaceuticos Rovi has a 52-week low of C$65.86 and a 52-week high of C$67.17.
About Laboratorios Farmaceuticos Rovi
Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.
ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.
See Also
- Five stocks we like better than Laboratorios Farmaceuticos Rovi
- Abercrombie’s Comeback Is a Work in Progress
- Roku’s Ad Business Is Growing—These 3 Stocks Could Be Next
- Cleared for Takeoff: Archer Aviation Changes the Math on eVTOL
- Voyager Technologies: Space Force Deal Fuels Growth Despite Heavy Cash Burn
Receive News & Ratings for Laboratorios Farmaceuticos Rovi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratorios Farmaceuticos Rovi and related companies with MarketBeat.com's FREE daily email newsletter.
